Alicia L. Otton

Array ( [id] => 16621402 [patent_doc_number] => 20210040055 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => FURAN BASED COMPOSITIONS AND METHODS OF MAKING THEREOF [patent_app_type] => utility [patent_app_number] => 16/639314 [patent_app_country] => US [patent_app_date] => 2018-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16894 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16639314 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18044820 [patent_doc_number] => 11518761 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-06 [patent_title] => CDPK1 inhibitors, compositions, and methods related thereto [patent_app_type] => utility [patent_app_number] => 16/639507 [patent_app_country] => US [patent_app_date] => 2018-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31694 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16639507 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17680009 [patent_doc_number] => 11364240 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-21 [patent_title] => Pyruvate kinase activators for use in treating blood disorders [patent_app_type] => utility [patent_app_number] => 16/639075 [patent_app_country] => US [patent_app_date] => 2018-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 7 [patent_no_of_words] => 58160 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 350 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16639075 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16238187 [patent_doc_number] => 20200255421 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => TETRAHYDROPROTOBERBERINE COMPOUND, PREPARATION METHOD THEREFOR AND USES THEREOF, AND PHARMACEUTICAL COMPOSITION [patent_app_type] => utility [patent_app_number] => 16/639394 [patent_app_country] => US [patent_app_date] => 2018-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18076 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 363 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16639394 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16237195 [patent_doc_number] => 20200254429 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => PROCESS AND CATALYSTS FOR THE OXIDATION AND/OR AMMOXIDATION OF OLEFIN [patent_app_type] => utility [patent_app_number] => 16/637522 [patent_app_country] => US [patent_app_date] => 2018-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18372 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16637522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18013246 [patent_doc_number] => 11505528 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-22 [patent_title] => Inhibitors of microbially induced amyloid [patent_app_type] => utility [patent_app_number] => 16/636511 [patent_app_country] => US [patent_app_date] => 2018-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 71 [patent_no_of_words] => 41611 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16636511 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16111423 [patent_doc_number] => 20200207734 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-02 [patent_title] => HETEROCYCLIC COMPOUND AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/633960 [patent_app_country] => US [patent_app_date] => 2018-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 77024 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16633960 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15395763 [patent_doc_number] => 10538525 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-21 [patent_title] => 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-ones as PDE1 inhibitors [patent_app_type] => utility [patent_app_number] => 16/051612 [patent_app_country] => US [patent_app_date] => 2018-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10905 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 189 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16051612 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15927865 [patent_doc_number] => 20200155566 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-21 [patent_title] => THERAPEUTIC COMBINATION OF A THIRD GENERATION EGFR TYROSINE KINASE INHIBITOR AND A CYCLIN D KINASE INHIBITOR [patent_app_type] => utility [patent_app_number] => 16/632954 [patent_app_country] => US [patent_app_date] => 2018-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13064 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16632954 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16511494 [patent_doc_number] => 20200390751 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-17 [patent_title] => ANTIFUNGAL AGENTS WITH ENHANCED ACTIVITY IN ACIDIC PH [patent_app_type] => utility [patent_app_number] => 16/636230 [patent_app_country] => US [patent_app_date] => 2018-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13405 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16636230 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15962903 [patent_doc_number] => 20200165203 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => USE OF PIRFENIDONE AND DERIVATIVES FOR MODULATION OF B LYMPHOCYTE ACTIVITY AND ORGAN PROTECTION FROM ACUTE TISSUE DAMAGE [patent_app_type] => utility [patent_app_number] => 16/638424 [patent_app_country] => US [patent_app_date] => 2018-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25133 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16638424 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19826246 [patent_doc_number] => 12247011 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-11 [patent_title] => Selective inhibitors of NLRP3 inflammasome [patent_app_type] => utility [patent_app_number] => 16/635374 [patent_app_country] => US [patent_app_date] => 2018-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52175 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16635374 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13575013 [patent_doc_number] => 20180339055 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-29 [patent_title] => BONE TARGETED THERAPEUTICS AND METHODS OF MAKING AND USING THE SAME [patent_app_type] => utility [patent_app_number] => 16/048125 [patent_app_country] => US [patent_app_date] => 2018-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8067 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16048125 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16704335 [patent_doc_number] => 10954255 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-23 [patent_title] => Phospholipid analogues [patent_app_type] => utility [patent_app_number] => 16/635883 [patent_app_country] => US [patent_app_date] => 2018-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 12 [patent_no_of_words] => 10979 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 176 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16635883 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13565807 [patent_doc_number] => 20180334451 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-22 [patent_title] => SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS [patent_app_type] => utility [patent_app_number] => 16/046332 [patent_app_country] => US [patent_app_date] => 2018-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 83805 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16046332 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13870647 [patent_doc_number] => 20190031664 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-31 [patent_title] => TYK2 INHIBITORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/046481 [patent_app_country] => US [patent_app_date] => 2018-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 296937 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16046481 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18186356 [patent_doc_number] => 11576914 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-14 [patent_title] => Drug for treating or preventing disorder caused by TGF-b signaling, and application thereof [patent_app_type] => utility [patent_app_number] => 16/634023 [patent_app_country] => US [patent_app_date] => 2018-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 21568 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16634023 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16297721 [patent_doc_number] => 20200283444 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-10 [patent_title] => SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/635887 [patent_app_country] => US [patent_app_date] => 2018-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11062 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 310 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16635887 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14043335 [patent_doc_number] => 20190077774 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-14 [patent_title] => PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AGONISTS [patent_app_type] => utility [patent_app_number] => 16/039001 [patent_app_country] => US [patent_app_date] => 2018-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46957 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16039001 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17281675 [patent_doc_number] => 11198695 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-14 [patent_title] => Fused ring derivative having MGAT-2 inhibitory activity [patent_app_type] => utility [patent_app_number] => 16/628753 [patent_app_country] => US [patent_app_date] => 2018-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44239 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 242 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16628753 [rel_patent_id] =>[rel_patent_doc_number] =>)